We are excited to virtually dive into the latest cancer research at #ASCO20. We will be sharing results from a first-in-human Phase 1 study of SRF231, a fully human, high-affinity anti-CD47 antibody (abstract 3064). #biotech #Immunooncology More info here: https://t.co/2K0iJKXB6M https://t.co/ZahYjZ5k1N